I had hoped that we add to our ocular presentation.
Tellingly, the CNS presentation was only shared during conference as this is more market and competition sensitive in regard to other companies.
Dual approach in Phelan McDermid Syndrome very impressive and showing depth of multiple pathways., possibly applicable to other programs.
Financial developments around the corner, possibly securing CEO's 18 mil share issuance as shareholders would be supportive on the heels of such news..
lots to look forward to in the next 6 months.
all IMO
I had hoped that we add to our ocular presentation.Tellingly,...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $17.86K | 137.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1081168 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 505604 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |